MDxHealth « Terug naar discussie overzicht

MDxHealth news 2012

467 Posts, Pagina: 1 2 3 4 5 6 ... 20 21 22 23 24 » | Laatste
Nel
0
MDxHealth Receives 2011 European Molecular Diagnostics for Oncology Technology Leadership Award january 9 2012

MDxHealth Receives CLIA Certification and California State License for its Clinical Laboratory 23 january 2012

finance.yahoo.com/news/Time-Exact-Sci...
verplaatst naar nabeurstijd!wellicht news from exact . 7 feb 2012

dit draadtje is voor de komende mnd waar nieuwe berichtgeving wordt verwacht.

February 21-23, 2012

MDxHealth to Present at Molecular MedTRI-CON 2012

www.triconference.com/mdx

Nel
1
2012 Newsflow

H1 – Publication Prostate biopsy tissue minimization Study
H1 - New companion diagnostic deal with pharma
H1 – First Prostate service testing offered
H1 – Presenting data from US prostate cancer trial
H1- Publishing results of Health economic study
H2 – CE marking of MGMT assay
H2 - Expected first revenue from Prostate ConfirmMDx
H2 – Submission of Exact Sciences colorectal cancer data to the FDA
H2 – Publication of Prostate Cancer studies
H2 – Publication Lung ConfirmMDx data
H2 – Additional Laboratory State Licensees

genoeg teverwachten
Nel
0
Take aways on UBS conference. 8-Feb-12 07:18 am

New stuff...

Finally, a worldwide perspective. KC mentioned India & China as future markets, but did not indicate any specifics. Also, on the automation front...he expects automation to be ready by the time all of the samples are collected (September of this year?) $3B between US (30% mkt penetration) and EU (10% mkt penetration). EU ranks highest in incidence and mortality of crc. 63.8 million shares fully diluted.
Nel
0
quote:

NEL schreef op 7 februari 2012 11:34:

2012 Newsflow

H1 – Publication Prostate biopsy tissue minimization Study
H1 - New companion diagnostic deal with pharma
H1 – First Prostate service testing offered
H1 – Presenting data from US prostate cancer trial
H1- Publishing results of Health economic study
H2 – CE marking of MGMT assay
H2 - Expected first revenue from Prostate ConfirmMDx
H2 – Submission of Exact Sciences colorectal cancer data to the FDA
H2 – Publication of Prostate Cancer studies
H2 – Publication Lung ConfirmMDx data
H2 – Additional Laboratory State Licensees

genoeg teverwachten
Publication Prostate biopsy tissue minimization Study
vandaag of morgen!!
Nel
0
als de koers spoedig boven de 2+ noteert hahahahaha

vandaag!!zou voorkennis zijn alvorens :

February 21-23, 2012

MDxHealth to Present at Molecular MedTRI-CON 2012

www.triconference.com/mdx

begint.

nabeurs of morgen wellicht news vanuit MDx kamp

Nel
0
newsflow 2012 zegt voldoende.

bedrijf gaat na jaren eindelijk zich opmaken naar een cashflow bedrijf.

succes
Nel
0
March 21-22, 2012

MDxHealth To Present at Kempen & Co Healthcare/Life Sciences Conference

Nel
0
•Q4 2011 Exact Sciences Corp Earnings Release - Before Market OpenCCBN(Thu 7:07AM EST)
Nel
0
“We are pleased that the DeeP-C clinical trial for our Cologuard®product, a noninvasive colorectal cancer screening test, remains on track,” said Kevin T. Conroy, president and chief executive of Exact. “During 2012, our priorities are completing the DeeP-C trial, making our FDA submission, and continuing our manufacturing and marketing preparation. All of us at Exact are focused on bringing to market our patient-friendly screening test, which enables early detection of colorectal cancer.”
Debit or Credit
0
Belangrijk nieuwsfeitje! Zou me niets verbazen als de pharmadeal van exact sc zou komen.
467 Posts, Pagina: 1 2 3 4 5 6 ... 20 21 22 23 24 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd 1 jan 0001
Koers 0,000
Verschil 0,000 (0,00%)
Hoog 0,000
Laag 0,000
Volume 0
Volume gemiddeld 0
Volume gisteren 0

EU stocks, real time, by Cboe Europe Ltd.; Other, Euronext & US stocks by NYSE & Cboe BZX Exchange, 15 min. delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by: Infront